| Jan 13, 2026 | Enspire DBS Therapy | $10.3M Series B | Jamie Stiff | Cleveland Clinic, JobsOhio Ventures |
| Jun 20, 2023 | Veralox Therapeutics | $24.0M Other Equity | — | Hatteras Venture Partners, JDRF T1D Fund, Meg Wood, Peter Young, Sanofi Ventures |
| Oct 1, 2022 | Inversago Pharma | $69.0M Series C | New Enterprise Associates | Accel, Advent Life Sciences, Amorchem, Atlas Venture, Benchmark, Bond, Forbion, Longwood Fund, Matrix, Ed Mathers, Novartis Venture Fund, Soffinova Partners, Sofinnova Investments, adMare BioInnovations, Amgen Ventures, JDRF |
| Jun 1, 2021 | Veralox Therapeutics | $17.0M Series A | Hatteras Venture Partners | T1D Fund, Alexandria Venture Investments, Jamie Stiff, JDRF T1D Fund, Maryland Momentum Fund, Point Field Partners, Sanofi Ventures, TEDCO, VTC Innovation Fund |
| May 1, 2021 | Giiant Pharma | $12.0M Seed | Jean-François Pariseau, Jamie Stiff | Amplitude VC, Mott Family Capital, OrbiMed, AmorChem, Anges Québec, Theodorus |
| Jan 1, 2020 | IDbyDNA | $20.0M Series B | — | Abstract Ventures, Artis Ventures (AV), Astanor Ventures, Texas Halo Fund |
| Nov 1, 2019 | EBT Medical | $10.0M Series A | Genesys Capital, Greg Madden | SV Health Investors |
| Apr 2, 2019 | Fusion | $105.0M Series B | Chau Khuong, Deepak Khuntia | Adams Street Partners, FACIT, HealthCap, Johnson & Johnson Innovation, Perceptive Advisors, Heather Preston, Rock Springs Capital, Alan O'Connell, TPG Biotech |
| Mar 1, 2019 | Fusion Pharmaceuticals | $110.0M Series B | OrbiMed, Deepak Khuntia | ARCH Venture Partners, Avalon Ventures, Domain Associates, Osage University Partners, Pivotal bioVenture Partners, RiverVest, Seroba Life Sciences, Sofinnova Investments, Third Rock Ventures, Heather Preston, Adams Street Partners, FACIT, HealthCap, Johnson & Johnson Innovation, Perceptive Advisors, Rock Springs Capital, TPG Biotech |
| Jul 1, 2018 | Inversago Pharma | $7.0M Series A | Amorchem, Jamie Stiff | Forbion, Ed Mathers, Accel-Rx Health Sciences Accelerator, Anges Québec, Anges Québec Capital, JDRF T1D Fund, Tarnagulla Ventures |
| Sep 1, 2017 | Fusion Pharmaceuticals | $21.0M Series A | — | Seroba Life Sciences, Terry Gould, FACIT, HealthCap, Johnson & Johnson Innovation, TPG Biotech, Varian Medical Systems |
| Feb 23, 2017 | Fusion Pharmaceuticals | $25.0M Series A | Asish Xavier | FACIT, Damian Lamb, Johan Christenson, Eran Nadav |
| Dec 1, 2014 | Naurex | $80.0M Series C | — | ALSA Ventures, Soffinova Partners, Adams Street Partners, Baxter Ventures, Cowen Healthcare Investments, Druid BioVentures, Oleg Nodelman, Goudy Park Capital, H. Lundbeck, Latterell Venture Partners, Northwestern University, Portola Capital Partners, Sabby Capital, Savitr Capital, Takeda Ventures |
| Oct 1, 2014 | Invitae | $120.0M Series F | — | Acorn Bioventures, Aisling Capital, HealthQuest Capital, Hercules Capital, Casey Tansey, Randy Scott, Thomas McNerney, Casdin Capital, Decheng Capital, Deerfield Management, Genomic Health, OrbiMed, Perceptive Advisors, Redmile Group, Rock Springs Capital, The Broe Group, Thomas, McNerney & Partners, Wellington Management |
| Dec 1, 2013 | Invitae | $40.0M Series E | — | HealthQuest Capital, Randy Scott, Casdin Capital, Genomic Health, Redmile Group, Thomas, McNerney & Partners |
| Dec 17, 2012 | Naurex | $38.0M Series B | Norbert Rieidel | Adams Street Partners, Druid BioVentures, H. Lundbeck, Latterell Venture Partners, Northwestern University, PathoCapital, Ian Ferrier, Shire, Takeda Ventures |
| Apr 13, 2012 | Tioga Pharmaceuticals | $10.0M Series B | Jason Brown | — |
| Sep 6, 2011 | gIcare Pharma | $7.1M Series A | Sander van Deventer, Genesys Capital | — |
| May 1, 2011 | Naurex | $18.0M Series A | Terry Gould, ken widder | ALSA Ventures, Soffinova Partners, Druid BioVentures, H. Lundbeck, Bill Gantz, Shire, Takeda Ventures |
| Nov 11, 2010 | Functional Neuromodulation | $600K Seed | Kelly Holman | — |
| Feb 17, 2010 | Tioga Pharmaceuticals | $18.0M Other Equity | — | BB Biotech Ventures, Forward Ventures, New Leaf Venture Partners |
